Ebola Virus Triage Test Granted Emergency Use Authorization
|
By LabMedica International staff writers Posted on 14 Jun 2016 |
|
Image: The Idylla fully automated, real-time polymerase chain reaction (rt-PCR) based molecular diagnostics system (Photo courtesy of Biocartis).
The 2014 Ebola virus outbreak in West Africa was the largest outbreak since its discovery 40 years ago and with over 11,000 deaths reported and affecting multiple countries, that outbreak demonstrated a clear need for improved infectious disease surveillance and management.
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Technology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
